Medicure(MCUJF)
Barbados - HoletownBiotechnology
Focus: Medicure is a small-molecule cardiovascular and metabolic biotech company publicly traded on the TSXV, generating 100% of revenue from its lead product ZYPITAMAG (pitavastatin magnesium).
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Medicure
AI assessmentNot HiringNo open roles listed right now. Follow Medicure to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Medicure's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
1 in 5yr
ZYPITAMAG
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$4M Part DStable
Peak4.2yr
Sole revenue driver; commercially established but faces patent expiration in 2031 with no approved successor.
Help build intelligence for Medicure
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.